Gemtesa is a prescription medication approved to treat overactive bladder (OOB) with symptoms of urinary urgency, frequency, and incontinence [1]. The 75mg dosage is one of the available strengths for this treatment [1][2].
What is Gemtesa used for?
Gemtesa, containing the active ingredient vibegron, is prescribed for adult women experiencing overactive bladder [1]. This condition is characterized by sudden, compelling urges to urinate, frequent urination, and involuntary leakage of urine [1].
How does Gemtesa work?
Vibegron works by relaxing the detrusor muscle in the bladder wall. This muscle contracts during bladder filling and is responsible for emptying the bladder. By relaxing this muscle, vibegron helps to increase bladder capacity and reduce the involuntary contractions that lead to OOB symptoms [3]. It acts as a beta-3 adrenergic agonist, a mechanism that targets specific receptors in the bladder [3].
What are the available dosages of Gemtesa?
Gemtesa is available in two tablet strengths: 75 mg and 175 mg [2]. The 75mg dosage is a commonly prescribed option for patients initiating treatment or as directed by a healthcare provider [1][2].
When does Gemtesa patent exclusivity expire?
Information regarding specific patent expiry dates for Gemtesa is available through specialized resources. DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceutical products, which can indicate when generic versions may become available [4].
What are the potential side effects of Gemtesa?
Common side effects reported with Gemtesa include headache, nasopharyngitis (common cold symptoms), diarrhea, nausea, and upper respiratory tract infection [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does Gemtesa compare to other OOB treatments?
Gemtesa offers an alternative mechanism of action compared to older OOB medications, such as anticholinergics [3]. While anticholinergics work by blocking acetylcholine in the bladder, vibegron targets beta-3 adrenergic receptors [3]. This difference in mechanism may lead to a different side effect profile for some patients, with Gemtesa generally having fewer anticholinergic side effects like dry mouth or constipation [3].
Who manufactures Gemtesa?
Gemtesa is manufactured by Urovant Sciences [5].
Sources:
[1] https://www.gemtesa.com/
[2] https://www.drugs.com/availability/gemtesa.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348278/
[4] https://drugpatentwatch.com/
[5] https://www.urovant.com/